Please login to the form below

Not currently logged in
Email:
Password:

MHRA launches medicines side effects awareness drive

Creates social media campaign as part of EU-wide initiative
MHRA SCOPE social media campaign still

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has launched a social media campaign on the importance of reporting suspected side effects.

As part of the EU-wide Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) project, from 7-11 November the regulator aims to raise awareness of adverse drug reactions and improve the public's understanding of how to report them.

Most reporting systems suffer from underreporting and the agency hopes the SCOPE initiative will strengthen its system's cache as a result.

Mick Foy, group manager for MHRA's vigilance and risk management for its medicines division, said: “The most important part of our work is making sure the medicines you and your family take are effective and acceptably safe.

“Our campaign will help the public, patients and healthcare professionals report potential side effects and have confidence that their reports are making a difference.”

The campaign centres on an animation of a patient who has a suspected adverse reaction to a treatment. As the story unfolds, it shows how patients and healthcare professionals make reports to the MHRA and their benefit to future patients.

The MHRA credits such reports for action including no longer prescribing aspirin to children, which resulted in the virtual elimination of Reye's syndrome cases in many EU countries.

Foy added: “You can help make medicines safer by reporting any suspected side effects easily and quickly through our Yellow Card Scheme online or via the mobile app.”

Article by
Rebecca Clifford

4th November 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics